UNSPSC 51314357: Citric/ipecac/potassium/promethazine/sodium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314357 Citric/ipecac/potassium/promethazine/sodium citrate is a Commodity code that in practice covers pharmaceutical products and supply chain management for state and local health and human services procurement, though the recent solicitations reveal a broader set of actual purchases spanning naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesale channels. State and local health departments, multistate cooperative purchasing alliances, and county health agencies issue solicitations under this code. Vendors typically must maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, establish relationships with authorized pharmaceutical wholesalers, provide detailed National Drug Code (NDC) and product information, and meet specific insurance thresholds including commercial general liability and professional liability coverage. Contracts commonly run two years with renewal options and impose administrative fees or performance penalties tied to reporting timeliness, onboarding compliance, and product availability.

Geographic activity centers on Florida and the upper Midwest cooperative purchasing region. Recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) for direct-to-manufacturer prescription program vendor capabilities, functioning as a preliminary market-intelligence phase before formal RFP issuance; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon, through AmerisourceBergen, Cardinal Health, and Morris & Dickson with awards effective July 1, 2026. MMCAP's evaluation weights price competitiveness at 75 percent and requires vendors to demonstrate pricing flexibility through multiple formats (flat price, net price, WAC-minus structures) and maintain relationships with at least two of three authorized wholesalers with chargeback systems in place.